Priority Lists
Protocol Posting of
Activations
Phase II Trial of Surgery with Perioperative INGN 201 (Ad5CMV-p53) Gene Therapy Followed by Chemoradiotherapy for Advanced, Resectable Squamous Cell Carcinoma of the Oral Cavity, Oropharynx, Hypopharynx and Larynx
| Study Coordinator(s) | George Yoo, M.D., S.G. Urba, M.D., Harold Kim, M.D., Ehab Hanna, M.D. |
| Participants | Limited: Institutions Listed on the Title Page |
Docetaxel (NSC-628503), Cisplatin (NSC-119875), and 5-Fluorouracil (NSC-19893) Induction Chemotherapy Followed by Accerlerated Fractionation/Concomitant Boost Radiation and Concurrent Single Agent Cisplatin (NSC-119875), in Patients with Advanced Squamous Cell Head and Neck Cancer
| Study Coordinator(s) | David J. Adelstein, M.D., Ehab Hanna, M.D., P.G. Shankar Giri, M.D., S.G. Urba, M.D. |
| Participants | Members, NCORP, Medical Oncologists, Radiation Oncologists, Surgeons, Pathologists |
Closures
Permanent Closure
A Two-Part Study of the Treatment of Atypical Endometrial Hyperplasia: Part A: A Prospective Study of Immediate Hysterectomy; Part B: A Randomized Phase II Study of Medroxyprogesterone Acetate Versus Depoprovera
| Participants | Members, NCORP, Surgeons, Pathologists |
Permanent Closure
Phase II Study of Dexamethasone/Alpha Interferon In AL Amyloidosis
| Study Coordinator(s) | Madhav V. Dhodapkar, M.D., Alan Solomon, M.D. |
| Participants | Pathologists, CALGB, NCORP, Members |
| Closure Date | 2003-03-15 |
Amendments, Revisions, Memoranda
Memorandum
A Randomized Phase III Trial of Combinations of Oxaliplatin (OXAL), 5-Fluorouracil (5-FU) and Irinotecan (CPT-11) as Initial Treatment of Patients With Advanced Adenocarcinoma of the Colon and Rectum
| Study Coordinator(s) | Stephen K. Williamson, M.D. |
| Participants | Members, Surgeons, NCORP |
Memorandum
Evaluation of Interferon Alpha-2b and Thalidomide in Patients with Disseminated Malignant Melanoma, Phase II
| Study Coordinator(s) | Laura F. Hutchins, M.D., Joseph I. Clark, M.D. |
| Participants | Members, NCORP, Medical Oncologists |
Revision #3
A Phase II Trial of a D1/3-MAGE-3-His Fusion Protein (NSC-719274) with Adjuvant SB-AS02B (NSC-719275) for Patients with Selected Stage IV, M1a or M1b Metastatic Melanoma
| Study Coordinator(s) | Jeffrey S. Weber, M.D., Vernon K. Sondak, M.D., Mary L. Disis, M.D. |
| Participants | Limited: Institutions Listed on the Title Page |
Revision #1
Evaluation of Intravenously Administered Tirapazamine Plus Cisplatin in Cervical Cancer, Phase II.
| Study Coordinator(s) | Harriet O. Smith, M.D., Geoffrey R. Weiss, M.D. |
| Participants | Members, Surgeons, NCORP |
Memorandum
A Phase III Trial of Dexamethasone, Cyclophosphamide, Etoposide, Cisplatin (DCEP) and G-CSF With or Without Thalidomide (NSC #66847) as Salvage Therapy for Patients with Refractory Multiple Myeloma
| Study Coordinator(s) | Mohamad A. Hussein, M.D., James K. Weick, M.D. |
| Participants | NCORP, Members |
Memorandum
A Phase II Trial of R115777 (NSC #70818) in Patients with Advanced Colorectal Cancer.
| Study Coordinator(s) | Robert P. Whitehead, M.D., John S. Macdonald, M.D. |
| Participants | Members, NCORP, Medical Oncologists |
Revision #5
Lung Cancer Specimen Repository Protocol, Ancillary
| Study Coordinator(s) | Wilbur A. Franklin, M.D., Paul H. Gumerlock, Ph.D., David R. Gandara, M.D. |
| Participants | Members, NCORP, Medical Oncologists, Pathologists, CTSU, NCIC-CTG, ECOG |
Other New Items
- IP - Pts Must Be Informed
- AC - Consent Must Be Amended
- CBR - No Registration Allowed until IRB Review
- RC - Formal Re-consent Required
- FBR - Full Board Review Required
- ER - Expedited Review Acceptable
- NR - No IRB Review Required